KPTI vs. ELYM, CTMX, VTGN, FGEN, NVCT, RPTX, OPTN, SGMT, CTXR, and COYA
Should you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include Eliem Therapeutics (ELYM), CytomX Therapeutics (CTMX), Vistagen Therapeutics (VTGN), FibroGen (FGEN), Nuvectis Pharma (NVCT), Repare Therapeutics (RPTX), OptiNose (OPTN), Sagimet Biosciences (SGMT), Citius Pharmaceuticals (CTXR), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical preparations" industry.
Eliem Therapeutics (NASDAQ:ELYM) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, community ranking, dividends, media sentiment and analyst recommendations.
Karyopharm Therapeutics has a consensus target price of $5.67, indicating a potential upside of 319.75%. Given Eliem Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Eliem Therapeutics.
Eliem Therapeutics has a net margin of 0.00% compared to Eliem Therapeutics' net margin of -97.99%. Eliem Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.
69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 3.3% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Karyopharm Therapeutics received 516 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 72.02% of users gave Karyopharm Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
Eliem Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Eliem Therapeutics had 4 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 4 mentions for Eliem Therapeutics and 0 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.21 beat Eliem Therapeutics' score of 0.00 indicating that Eliem Therapeutics is being referred to more favorably in the media.
Eliem Therapeutics has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500.
Summary
Eliem Therapeutics and Karyopharm Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Karyopharm Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Karyopharm Therapeutics Competitors List
Related Companies and Tools
